Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Spleen tyrosine kinase (SYK) inhibitor | Spleen tyrosine kinase (SYK) inhibitor | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[ | + | ===[[Chronic lymphocytic leukemia]]=== |
| − | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www. | + | # '''GS-US-339-0102:''' Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [https://doi.org/10.1182/blood-2014-08-595934 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4401348/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25696919/ PubMed] [https://clinicaltrials.gov/study/NCT01799889 NCT01799889] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' GS-9973 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:SYK inhibitors]] | [[Category:SYK inhibitors]] | ||
| + | [[Category:Chronic lymphocytic leukemia medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 18:21, 27 June 2024
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
Chronic lymphocytic leukemia
- GS-US-339-0102: Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article link to PMC article PubMed NCT01799889
Also known as
- Code name: GS-9973